Kodiak Sciences' Pipeline Shows Promise Amid Financing Challenges
Kodiak Sciences details retinal drug pipeline
Kodiak Sciences’ 10-K highlights Zenkuda Phase 3 successes, an expanding KSI-501 and KSI-101 pipeline, Lonza-backed manufacturing, and a disclosed going-concern risk tied to future financing and pivotal readouts from 3Q 2026 onward.
Kodiak Sciences released its 10-K filing detailing strong Phase 3 progress for Zenkuda and expansion of its KSI-501 and KSI-101 pipeline programs for retinal diseases. The biotech company, backed by manufacturing partner Lonza, disclosed going-concern risks dependent on future financing and critical pivotal trial readouts expected in Q3 2026 and beyond.
Original Article
Read full article on sourceExplore More
Related News
Unlocking Replicability: The Seven-Year Journey in Social Sciences | Science-Environment
Devdiscourse · 2026.04.04
Longtime leader in health sciences education appointed dean of Mizzou’s College of Health Sciences
Show Me Mizzou · 2026.04.03
BRUNO KARSENTI JOINS SCIENCES PO
2026.04.03
BREAKING: MTSU mathematical sciences professor dead
Sidelines | Middle Tennessee State University’s Digital News Source · 2026.04.03
Local science students invited to National Competition
paNOW · 2026.04.05
Galactic Explosions and Lunar Expeditions: A New Era in Space Science | Science-Environment
Devdiscourse · 2026.04.05